Detection and Quantification of KIT Mutations in CtDNA by Plasma Safe-SeqS

Overview

Journal Adv Exp Med Biol

Specialties Biology
General Medicine

Date 2016 Oct 19

PMID 27753042

Citations 11

Authors

Johannes Fredebohm

Daniel H Mehnert

Ann-Kathrin Lober

Frank Holtrup

Vanessa van Rahden

Philipp Angenendt

Frank Diehl

Affiliations

Soon will be listed here.

Abstract

We have designed a highly sensitive assay based on the Safe-SeqS technology to detect de novo mutations in the KIT gene and tested its performance. This assay was applied to plasma samples of GIST patients before and after treatment with regorafenib (GRID III trial) and mutations at known and novel sites of potential secondary resistance were identified.

Citing Articles

Beyond traditional biopsies: the emerging role of ctDNA and MRD on breast cancer diagnosis and treatment.

Sabit H, Attia M, Mohamed N, Taha P, Ahmed N, Osama S Discov Oncol. 2025; 16(1):271.

PMID: 40050490 PMC: 11885725. DOI: 10.1007/s12672-025-01940-6.

Liquid Biopsy in Pancreatic Ductal Adenocarcinoma: A Review of Methods and Applications.

Dubrovsky G, Ross A, Jalali P, Lotze M Int J Mol Sci. 2024; 25(20).

PMID: 39456796 PMC: 11507494. DOI: 10.3390/ijms252011013.

The Evolution of Affordable Technologies in Liquid Biopsy Diagnostics: The Key to Clinical Implementation.

Alexandrou G, Mantikas K, Allsopp R, Yapeter C, Jahin M, Melnick T Cancers (Basel). 2023; 15(22).

PMID: 38001698 PMC: 10670715. DOI: 10.3390/cancers15225434.

Circulating Tumor DNA and Minimal Residual Disease (MRD) in Solid Tumors: Current Horizons and Future Perspectives.

Peng Y, Mei W, Ma K, Zeng C Front Oncol. 2021; 11:763790.

PMID: 34868984 PMC: 8637327. DOI: 10.3389/fonc.2021.763790.

Liquid Biopsy in Colorectal Carcinoma: Clinical Applications and Challenges.

Kolencik D, Shishido S, Pitule P, Mason J, Hicks J, Kuhn P Cancers (Basel). 2020; 12(6).

PMID: 32471160 PMC: 7352156. DOI: 10.3390/cancers12061376.